A formulation comprising hyaluronic acid for use in the treatment of premature ejaculation

WO2024237896A1PCT designated stage Publication Date: 2024-11-21VSY BIYOTEKNOLOJI VE ILAC SANAYI AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/TR2024/050492
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-05-16
Publication Date
2024-11-21

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

The present invention relates to a formulation comprising hyaluronic acid for use in the treatment of premature ejaculation, wherein the formulation comprising hyaluronic acid (HA) is injected as a bulking formulation into the dermis of the glans or the dermis of the frenulum of the prepuce to delay the ejaculatory reflex. The present invention also provides effectiveness in terms of mechanical bulking for the glans penis and penis, and biologically promotes the development of penile tissue with the swelling / growth factors it contains.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] A FORMULATION COMPRISING HYALURONIC ACID FOR USE IN THE TREATMENT OF PREMATURE EJACULATION

[0002] Field of the Invention

[0003] The present invention relates to a formulation comprising hyaluronic acid for administration by injection into the dermis of the glans or the dermis of the frenulum of the prepuce for use in the treatment of premature ejaculation.

[0004] Background of the Invention

[0005] Premature ejaculation (PE), which is known as the most common male sexual dysfunction today, is a common male sexual dysfunction that creates tension and relationship problems between couples. It has been reported in the studies that the population with this disorder is between 20% and 30% worldwide [1] .

[0006] The most recent definition of PE was provided by the International Society for Sexual Medicine (ISSM) in its 2013 guidelines. Summaries of the definitions made according to this guideline are as follows:

[0007] Lifelong PE: It is present from the first sexual intercourse. Intravaginal ejaculation latency time (IELT) is within 30-60 seconds in 80% of cases and within 1-2 minutes (min) in 20% of cases. It happens with every partner and every relationship. There may be genetic or neurobiological causes in its etiology.

[0008] Acquired PE: The patient has a normal ejaculation time until the onset of PE. Ejaculation time is under 1.5-2 minutes. Thyroid disorders, urologic or psychological problems have been implicated in the etiology.

[0009] Natural variable PE: The ejaculation time is not always short, and the problem may be associated with certain conditions. This is more of a variation within the normal range of sexual performance rather than an actual pathology. Psychotherapy is more useful in treatment.

[0010] Premature-like ejaculation disorder: Ejaculation time is within normal limits (3-6 minutes), but they mistakenly think that their ejaculation time is very short. It may be due to relationship problems and psychological reasons.

[0011] The treatment of premature ejaculation has a wide range due to differences in both etiology and definitions. Initially, behavioral, and psychosexual therapies were used in treatment, but later it was focused on medical treatments due to limited results. The drugs used in medical treatment are mainly selective serotonin reuptake inhibitors (SSRIs) as well as phosphodiesterase-5 inhibitors (PDE-5inh), tramadol and alpha blockers.

[0012] Some of the PE treatment protocols that are known in the previous art are listed below:

[0013] Behavioral Therapy / Psvchosexual Therapies: This type of treatment seeks to achieve the following gains:

[0014] • Teaching control of ejaculation and delay techniques

[0015] • Restoring confidence in sexual performance

[0016] • Changing strict sexual opinions

[0017] • Removing the protection shields which the person form around themselves

[0018] • Improving interpersonal relations

[0019] Topical agents: Because of penile hypersensitivity, which is one of the theories blamed in the pathogenesis, topical agents were first used in treatment in 1940. For this reason, lidocaine and lidocaine-procaine mixture drugs, which are the most commonly used local anesthetic derivatives due to their rapid and short effect, are used. In a randomized double-blind placebo study, combined (lidocaineprilocaine) treatment was shown to prolong IELT (from 1 min to 6 mins) [2],

[0020] Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs were started to be used after the side effects of SSRIs on PE were recognized. The efficacy and safety of off-label use of SSRIs (paroxetine, sertraline, citalopram, fluoxetine and chlorimipramine) are known. The effect of SSRIs in the treatment of premature ejaculation starts in 5-10 days and the maximum effect is seen in 2-3 weeks. Even though the efficacy can be maintained for a long time, a decrease in sensitivity to the drug can also develop between 6-12 months. There are studies showing the superiority of paroxetine over fluoxetine, sertraline and chlorimipramine [3], Recently, there have been studies that SSRIs affect sperm motility and damage sperm DNA and impair sperm parameters, therefore they should not be recommended for patients who want to have children. Due to the side effects of SSRIs, they have been used when desired instead of every day; however, this requires drugs that are rapidly absorbed and rapidly eliminated and has been found to be less effective with on-demand use than with daily use.

[0021] Dapoxetine: It is a newly developed, fast-acting and short half-life SSRI derivative drug for the treatment of premature ejaculation. It is a strong drug which is metabolized mostly through the liver. With a maximum duration of effectiveness of approximately 1.5 hours and a half-life of 30 minutes, this agent is rapidly eliminated. It is recommended to be taken 1-3 hours before sexual intercourse. It is well tolerated in men with PE and it can be safely used in patients on PDE5-inh for erectile dysfunction. For this reason, it has often been the preferred agent for on-demand use.

[0022] It is a preparation developed solely for the treatment of PE and it is not used as an antidepressant or in anxiety disorders; unlike other SSRIs used as antidepressants, withdrawal syndrome, neurocognitive side effects (such as mood changes, anxiety, hypomania) are not experienced and sexual dysfunction is less common. Phosphodiesterase-5 inhibitors: There are studies on the effect of PDE5-inh alone or in combination on PE, which is used in the treatment of erectile dysfunction (ED), another problem in male sexual health. In the study with verdanafil, which is a PDE5-inh, it provided significant improvement in ejaculation control, sexual satisfaction and stress compared to placebo. In a randomized placebo-controlled study, significant improvement was achieved with PDE5-inh compared to placebo in patients with ED and PE [4], In the study conducted with sildenafil, it was found that sildenafil prolonged IELT slightly, but it was not statistically significant. In the study, it was stated that sildenafil decreased anxiety and increased self-confidence by increasing ejaculation control. It was shown that combined use of PDE5-inh and SSRI may be more effective than PDE5-inh alone, but side effects were also found to be higher. PDE5-inh alone is not indicated in people with normal erectile function, even though there is several evidence of efficacy in the treatment of PE.

[0023] Tramadol: Tramadol is a centrally acting opioid analgesic substance with an unclear mechanism of action. In the central nervous system (CNS), MI, its metabolite, binds to the opioid receptor to produce analgesic effects and inhibits GABA, norepinephrine and serotonin reuptake at low levels. Studies on this effect of tramadol are generally of low evidence level. In a randomized double-blind study, tramadol was shown to increase IELT 2.5-fold compared to placebo. A recent meta-analysis has shown that tramadol provides significant improvement compared to placebo in the treatment of PE [5] .

[0024] Alpha blockers: Alpha blockers, which have an important role in the treatment of lower urinary tract symptoms, have commonly seen sexual side effects such as retrograde ejaculation and anejaculation. It has been shown to exert these effects by reducing the sympathetic tonus of the seminal canal and delay ejaculation. The first study with phenoxybenzamine, a non-selective alpha blocker, provided significant improvement in PE. Subsequently, a study with terazosin, which is a selective alpha blocker, resulted in significant improvement in PE. Studies with silodosin, which is a new and potent alpha- 1 adrenergic blocker, have shown that silodosin increased IELT more than 3 -fold and in another study, it has been shown to increase sexual satisfaction by reducing anxiety and increasing ejaculation control in patients [6] .

[0025] The problems encountered in these said PE treatments are listed below: The side effect profile of topical treatments is not high, but hypoesthesia in partners and anorgasmia in the opposite sex due to transvaginal absorption can be seen, especially when condoms are not used. In addition to this, there is also a high risk of allergic reactions. Side effects resulting from the use of SSRIs are usually mild and do not last longer than 2 weeks, but weakness, fatigue, dry mouth, nausea, diarrhea are often seen. Anxiety, hypomania, akathisia and mood changes are seen as neurocognitive side effects, and in a randomized controlled trial, SSRIs have been found to cause suicidality, albeit low, in young patients with depressive symptoms [7], SSRIs should therefore be used with caution in young men. SSRIs that are used for male sexual health can cause loss of libido, anorgasmia and even erectile dysfunction in patients. Headache, nausea, malaise, weakness, diarrhea may be experienced due to dapoxetine use. The discontinuation rate due to side effects is around 5%, which is the same as for other SSRIs. The most common side effects of tramadol use are nausea, vomiting, weakness, fatigue and headache. Even though tramadol can be used in the treatment of PE, attention should be paid to the risk of addiction and serotonin syndrome, which can lead to death due to its combination with SSRIs. Sexual side effects such as retrograde ejaculation and anejaculation are seen with alpha blockers. From the problems described above, a new approach to PE treatment is needed in the art. A substance comprising hyaluronic acid for use in the treatment according to the present application fulfills said need.

[0026] Summary of the Invention

[0027] The objective of the present invention is to provide a formulation comprising hyaluronic acid for administration by injection into the dermis of the glans or the dermis of the frenulum of the prepuce for use in the treatment of premature ejaculation (PE). In addition to the effectiveness of the invention as a bulking formulation, the active formulation of hyaluronic acid (with the help of swelling / growth factors) which the invention comprises also has the effect of increasing the volume of penile vascular tissue and penis.

[0028] Detailed Description of the Invention

[0029] The invention is a formulation comprising hyaluronic acid for the treatment of premature ejaculation, characterized in that the formulation is administered by injection into the dermis of the glans or into the dermis of the frenulum of the prepuce. In other words, the present invention relates to a formulation comprising hyaluronic acid for administration by injection into the dermis of the glans or the dermis of the frenulum of the prepuce for use in the treatment of premature ejaculation. The formulation comprising hyaluronic acid according to the present invention has an advanced therapeutic use with its different function (its use in the treatment of premature ejaculation) and route of administration (injection into the dermis of the glans or the dermis of the frenulum of the prepuce).

[0030] The administration of the inventive formulation is carried out by injection into the dermis of the glans or the dermis of the frenulum of the prepuce. Therefore, a treatment which can be easily applied without the need for surgical methods has been proposed. Since a low level of invasive application is performed, a treatment with high patient comfort is provided and preferably the application can be performed without the need for local anesthesia.

[0031] The duration of use of the formulation of the invention is long enough for the patient administered with it to use for a lifetime, therefore, with a single administration, the patient gets rid of the problem of premature ejaculation for the rest of his life.

[0032] Non-pharmaceutical embodiments of the formulation according to the invention do not naturally comprise the active formulation. Thus, side effects caused by the active formulation of the drug will not be experienced. Embodiments of the formulation according to the present invention are suitable for use in combination with other treatment protocols.

[0033] The formulation comprising hyaluronic acid according to the invention has a biocompatible natural polymer-based content. The hyaluronic acid molecule is an efficient lubricant as well as being extremely polar, water-soluble and hypoallergenic. Therefore, the formulation comprising hyaluronic acid of the present invention is used as a filler formulation to increase the soft tissue volume in the dermis of the glans of the penis or in the dermis of the frenulum of the prepuce.

[0034] Hypersensitivity of the glans penis is a leading cause of premature ejaculation. This hypersensitivity of the glans penis can be reduced by “norectomy”, i.e. surgical cutting of the dorsal nerve, which is the sensory nerve of the glans penis. As this treatment is invasive, it causes permanent sensory loss, and it is not possible to restore the dorsal nerve. The formulation of the present application reduces the hypersensitivity of the frenulum of the glans penis or prepuce without causing permanent sensory loss. In addition to this, penis size is also increased. Thus, the patient's self-esteem and self-confidence are increased and the psychological effect, another factor that plays an important role in premature ejaculation, is significantly reduced.

[0035] Since the hyaluronic acid of the present invention is antigenic, pyrogenic, inflammatory, and non-toxic, its biocompatibility is high. Furthermore, the formulation of the present invention is easy to apply and use. After the injection of the formulation of the present invention, the formulation can maintain its stable position in the injected tissue area without migrating. The formulation of the present invention is long-lasting and can be reabsorbed. The formulation also responds to the patient's aesthetic concerns as it is natural -looking. Since it is difficult to understand that an administration has been made, it comforts the patient psychologically after the administration.

[0036] The formulation in an embodiment of the invention comprises hyaluronic acid at a concentration in the range of 5-30 mg / ml. It was observed that hyaluronic acid concentrations in the range of 5-30 mg / ml showed viscoelastic properties that facilitate use. Above the said concentration range, there may be problems in the dissolution of the formulation in the body. Below the said concentration range, the formulation becomes too viscous and injection becomes difficult.

[0037] The formulation in one embodiment of the invention comprises hyaluronic acid in the form of a crosslink. The formulation in a variation of an embodiment of the invention comprises hyaluronic acid having at least one of the agents of 1,4- butanediol diglycidyl ether (BDDE), divinyl sulfone (DVS), glutaraldehyde (GTA), adipic acid dihydrazide (ADH), poly diglycidyl ether (PDE) or l-Ethyl-3- (3 -dimethylaminopropyl) carbodiimide (EDC) / N-hydroxysuccinimide (NHS) as a crosslinker.

[0038] The formulation in one embodiment of the invention comprises hyaluronic acid in the form of a gel. The formulation in one embodiment of the invention comprises hyaluronic acid in the form of a gel having a particle size in the range of 50-1500 pm.

[0039] The formulation in one embodiment of the invention comprises hyaluronic acid having an elastic modulus in the range of 50-1500 Pa measured at 1 Hz.

[0040] The formulation in one embodiment of the invention comprises hyaluronic acid having a complex viscosity in the range of 5-200 Pa.s measured at 1 Hz.

[0041] The formulation in one embodiment of the invention comprises hyaluronic acid having a swelling factor in the range 2-20.

[0042] The formulation in one embodiment of the invention comprises hyaluronic acid having a crosslinking degree in the range 2-15.

[0043] In one embodiment of the invention, the formulation comprises hyaluronic acid with a content of unreacted cross-linker below 2 ppm.

[0044] In one embodiment of the invention, the said formulation is prepared and stored in ready-to-use syringes fdled in a volume in the range of 0.5-10 ml (preferably 1 ml) prior to administration. Then the syringe is sterilized by steam sterilization. These injectors are selected as an injector with a needle size in the range 27-30 G. It has been observed that the effects such as pain and bruising in the patient are reduced in administrations done with injectors with a needle size in the range of 27-30 G. The formulation according to the invention is preferably administered in a dose in the range of 0,5-40 ml (preferably 1 ml) within the scope of the invention. REFERENCES

[0045] [1]. Montorsi, Francesco. "Prevalence of premature ejaculation: a global and regional perspective." The journal of sexual medicine 2 (2005): 96- 102

[0046] [2]. Atikeler, M. K., I. Gecit, and F. A. Senol. "Optimum usage of prilocaine-lidocaine cream in premature ejaculation." Andrologia 34.6 (2002): 356-359

[0047] [3]. Waldinger, Marcel D., Aeilko H. Zwinderman, and Berend Olivier.

[0048] "SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram." Journal of clinical psychopharmacology 21.6 (2001): 556-560

[0049] [4]. Sun, Yi, et al. "Efficacy of phosphodiesterase-5 inhibitor in men with premature ejaculation: a new systematic review and meta-analysis." Urology 86.5 (2015): 947-955

[0050] [5]. James, Martyn-St, et al. "Tramadol for premature ejaculation: a systematic review and meta-analysis." BMC urology 15.1 (2015): 1-11

[0051] [6]. Bhat, Gajanan S., and Anuradha Shastry. "Effectiveness of ‘on demand’ silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study." Central European Journal of Urology 69.3 (2016): 280

[0052] [7]. Stone, Marc, et al. "Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration." Bmj 339 (2009)

Claims

CLAIMS1. A formulation comprising hyaluronic acid for use in the treatment of premature ejaculation, administered by injection into the dermis of the patient's glans dermis or the dermis of the frenulum of the prepuce.

2. A formulation according to claim 1, comprising hyaluronic acid at a concentration in the range of 5-30 mg / ml.

3. A formulation according to any one of the preceding claims, comprising hyaluronic acid in cross-link form.

4. A formulation according to claim 3, comprising hyaluronic acid having at least one of the agents of 1,4-butanediol diglycidyl ether (BDDE), divinyl sulfone (DVS), glutaraldehyde (GTA), adipic acid dihydrazide (ADH), poly diglycidyl ether (PDE) or l-Ethyl-3 -(3 -dimethylaminopropyl) carbodiimide (EDC) / N-hydroxysuccinimide (NHS) as a crosslinker.

5. A formulation according to any one of claim 3 or 4, comprising hyaluronic acid in gel form.

6. A formulation according to 5, comprising hyaluronic acid in gel form with a particle size in the range 50-1500 pm.

7. A formulation according to any one of claims 5-6, comprising hyaluronic acid having an elastic modulus in the range of 50-1500 Pa measured at 1 Hz.

8. A formulation according to any one of claims 5-7, comprising hyaluronic acid having a complex viscosity in the range of 5-200 Pa.s measured at 1 Hz.

9. A formulation according to any one of claims 5-8, comprising hyaluronic acid having a swelling factor in the range of 2-20.

10. A formulation according to any one of claims 5-9, comprising hyaluronic acid having a crosslinking degree in the range of 2-15.

11. A formulation according to any one of claims 5-10, comprising hyaluronic acid with a content of unreacted crosslinker at a value of less than 2 ppm.

12. A method for administering a formulation according to any one of the preceding claims, comprising administering the said formulation to the dermis of the patient's glans dermis or the dermis of the frenulum of the prepuce in a volume in the range of 0.5-40 ml13. A method of administration according to claim 12, wherein the said formulation is administered by an injector having a needle having a size in the range of 27-30 G.

14. A method of administration according to claim 12 or 13, wherein the said formulation is stored in a ready-to-use syringe in a volume in the range of 0.5- 10 ml prior to administration.

15. A method of administration according to any one of claims 12 to 14, wherein the said formulation is stored in a ready-to-use syringe sterilized by steam sterilization prior to administration.